Skip to content
Screener

Glaukos GKOS Total Equity

Total Equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.71B+5.9%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$52.89M-24.5%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Schering-Plough logo
Schering-PloughSGP
$250.11M+463%
Bausch + Lomb logo
Bausch + LombBLCO
$6.38B-1.0%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025--
Common stock, $0.001 par value; 150,000 shares authorized; 58,886 and 57,539 shares issued and 58,858 and 57,511 shares outstanding as of June 30, 2026 and December 31, 2025, respectively5958
Additional paid-in capital1,651,4651,586,056
Accumulated other comprehensive income2,3843,303
Accumulated deficit(971,290)(933,130)
Less treasury stock (28 shares as of June 30, 2026 and December 31, 2025)(132)(132)
Total stockholders' equity682,486656,155
Total liabilities and stockholders' equity$920,521$893,487

Item 1. Financial Statements

FAQ

What is Glaukos's total equity?
Glaukos (GKOS) reported total equity of $682.49M in Q2 2026.
How has Glaukos's total equity changed year-over-year?
Glaukos's total equity decreased by 10.8% year-over-year, from $765.11M to $682.49M.
What is the long-term trend for Glaukos's total equity?
Over 5 years (2020 to 2025), Glaukos's total equity has grown at a -0.3% compound annual growth rate (CAGR), from $667.45M to $656.16M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Glaukos's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude